About ASCIA Anaphylaxis e-training for health professionals

ASCIA Anaphylaxis e-training for health professionals 2021-2 ASCIA Anaphylaxis e-training for health professionals has been developed by ASCIA to provide accessible, consistent and evidence-based training for medical practitioners and other health professionals in Australia and New Zealand at no charge. ASCIA anaphylaxis e-training for health professionals has been updated in October 2021 (version 8.0) to include:

  • Updated and new ASCIA Action and First Aid Plans.
  • New infographics and animations to make the training more visual and interactive.
  • Instructions for two brands of adrenaline (epinephrine) injectors, EpiPen® and Anapen® .

ASCIA gratefully acknowledges all of the generous supporters of ASCIA education resources, as listed on the ASCIA website https://www.allergy.org.au/about-ascia/sponsors 

The learning outcomes for this course are: 

  • Differentiate between a mild to moderate allergic reaction and anaphylaxis.
  • Review diagnosis of allergy and risk of anaphylaxis.
  • Outline acute management for mild or moderate allergic reactions and anaphylaxis

Course instructions

  • A username and password must be obtained from the health professionals e-training website registration process to participate in a course.
  • The course comprises nine modules which ideally should be completed in order.
  • Modules 1-7 have evaluations that allow you to monitor your understanding.
  • The overall course assessment and certificate is provided in Module 8 where final assessment is undertaken for Modules 1-7.


  • You can undertake this course at your own pace.
  • To obtain a Certificate of Completion for ASCIA anaphylaxis e-training for health professionals a result of 100% is required for the Assessment in Module 8. If this result is not obtained on the first attempt, you may reattempt the assessment after reviewing the course content.
  • The Certificate of Completion is available as PDF for you to save or print for your own record. 
Last modified: Monday, 28 February 2022, 12:41 PM